Overview

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

Status:
Completed
Trial end date:
2019-11-08
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company